Drug Trial Radar · NCT01572792
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Apr 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
921
Actual
Start
Apr 2012
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). Long-term efficacy, pharmacoeconomic and health-related quality of life assessments will also be evaluated. This extension study will include a 28 week treatment period, followed by a four week follow up visit. All patients will remain in the same treatment group as for the lead-in study and continue on one of the four treatment arms or placebo.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)Drug
Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)Drug
Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
Aclidinium bromideDrug
Inhaled Aclidinium bromide 400 μg, twice per day
Formoterol FumarateDrug
Inhaled Formoterol Fumarate 12 μg, twice per day
PlaceboDrug
Inhaled dose-matched placebo, twice per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients to Experience Any Treatment-emergent Adverse EventTime frame: Baseline of lead-in study to follow-up call 14±3 days after last dose of investigational product (up to Week 52)
Locations
208 sites in 4 countries. Site status is shown where the registry gives one.
Forest Investigative Site 1827
Anniston, Alabama
Forest Investigative Site 1920
Athens, Alabama
Forest Investigative Site 1162
Birmingham, Alabama
Forest Investigative Site 1493
Birmingham, Alabama
Forest Investigative Site 1937
Birmingham, Alabama
Forest Investigative Site 1824
Gulf Shores, Alabama
Forest Investigative Site 2088
Jasper, Alabama
Forest Investigative Site 1918
Scottsboro, Alabama
Forest Investigative Site 0909
Glendale, Arizona
Forest Investigative Site 1379
Phoenix, Arizona
Forest Investigative Site 1822
Anaheim, California
Forest Investigative Site 1483
Buena Park, California
Forest Investigative Site 1156
Fresno, California
Forest Investigative Site 1871
Lincoln, California
Forest Investigative Site 1873
Los Angeles, California
Forest Investigative Site 2064
Riverside, California
Forest Investigative Site 1427
Sacramento, California
Forest Investigative Site 1866
Sacramento, California
Forest Investigative Site 1125
San Diego, California
Forest Investigative Site 2009
San Diego, California
Forest Investigative Site 1374
Torrance, California
Forest Investigative Site 1813
Tustin, California
Forest Investigative Site 1883
Vista, California
Forest Investigative Site 1380
Golden, Colorado
Forest Investigative Site 1137
Pueblo, Colorado
Forest Investigative Site 1327
Wheat Ridge, Colorado
Forest Investigative Site 1976
Waterbury, Connecticut
Forest Investigative Site 1821
Bay Pines, Florida
Forest Investigative Site 1154
Brandon, Florida
Forest Investigative Site 1944
Brandon, Florida
Forest Investigative Site 1364
Clearwater, Florida
Forest Investigative Site 1152
Clearwater, Florida
Forest Investigative Site 1875
Clearwater, Florida
Forest Investigative Site 1811
Covington, Florida
Forest Investigative Site 0670
DeLand, Florida
Forest Investigative Site 1516
Edgewater, Florida
Forest Investigative Site 0990
Fort Lauderdale, Florida
Forest Investigative Site 1513
Hialeah, Florida
Forest Investigative Site 1854
Hialeah, Florida
Forest Investigative Site 1882
Hollywood, Florida
Showing 40 of 208 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.